The median time to meningioma progression in the CDKN2A/B wild-type arm was 180.0 (95% CI 145.7–214.3) months, whereas in those with a homo- or heterozygous CDKN2A/B deletion median PFS time was 14.8 (95% CI 10.0–19.6) months (p < 0.0001). The gene discussed is CDKN2A; the disease is meningioma.